The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Cell Line

This is a "connection" page, showing publications Mary Eileen Dolan has written about Cell Line.
Connection Strength

1.838
  1. Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
    View in: PubMed
    Score: 0.106
  2. Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One. 2015; 10(2):e0118020.
    View in: PubMed
    Score: 0.092
  3. EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
    View in: PubMed
    Score: 0.085
  4. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
    View in: PubMed
    Score: 0.082
  5. Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics. 2013 Apr; 14(5):447-50.
    View in: PubMed
    Score: 0.081
  6. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
    View in: PubMed
    Score: 0.072
  7. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
    View in: PubMed
    Score: 0.072
  8. Population differences in microRNA expression and biological implications. RNA Biol. 2011 Jul-Aug; 8(4):692-701.
    View in: PubMed
    Score: 0.072
  9. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
    View in: PubMed
    Score: 0.072
  10. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33.
    View in: PubMed
    Score: 0.069
  11. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
    View in: PubMed
    Score: 0.065
  12. Expression and alternative splicing of folate pathway genes in HapMap lymphoblastoid cell lines. Pharmacogenomics. 2009 Apr; 10(4):549-63.
    View in: PubMed
    Score: 0.061
  13. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
    View in: PubMed
    Score: 0.060
  14. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53.
    View in: PubMed
    Score: 0.060
  15. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet. 2009 Mar; 125(2):173-80.
    View in: PubMed
    Score: 0.060
  16. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun; 64(1):133-42.
    View in: PubMed
    Score: 0.060
  17. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther. 2008 Sep; 7(9):3038-46.
    View in: PubMed
    Score: 0.059
  18. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics. 2008 Jun; 18(6):545-9.
    View in: PubMed
    Score: 0.058
  19. Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008 May; 82(5):1101-13.
    View in: PubMed
    Score: 0.057
  20. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
    View in: PubMed
    Score: 0.055
  21. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A. 2007 Jun 05; 104(23):9758-63.
    View in: PubMed
    Score: 0.054
  22. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther. 2007 Jan; 6(1):31-6.
    View in: PubMed
    Score: 0.052
  23. Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics. 2005 Apr; 6(3):303-10.
    View in: PubMed
    Score: 0.046
  24. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
    View in: PubMed
    Score: 0.045
  25. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res. 1999 Aug; 5(8):2059-64.
    View in: PubMed
    Score: 0.031
  26. Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
    View in: PubMed
    Score: 0.029
  27. Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics. 2015; 10(9):810-8.
    View in: PubMed
    Score: 0.024
  28. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
    View in: PubMed
    Score: 0.022
  29. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
    View in: PubMed
    Score: 0.018
  30. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72.
    View in: PubMed
    Score: 0.017
  31. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5368-72.
    View in: PubMed
    Score: 0.017
  32. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr; 20(4):269-73.
    View in: PubMed
    Score: 0.016
  33. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis. 1989 Sep; 10(9):1613-9.
    View in: PubMed
    Score: 0.016
  34. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8.
    View in: PubMed
    Score: 0.015
  35. Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res. 1986 Sep; 46(9):4500-4.
    View in: PubMed
    Score: 0.013
  36. 1,3- vs 1,5-intramolecular alkylation reactions in isophosphoramide and phosphoramide mustards. Chem Res Toxicol. 2004 Sep; 17(9):1217-26.
    View in: PubMed
    Score: 0.011
  37. Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. Mutat Res. 1991 Sep-Oct; 250(1-2):397-409.
    View in: PubMed
    Score: 0.005
  38. Depletion of O6-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1985 Dec; 6(12):1823-6.
    View in: PubMed
    Score: 0.003
  39. Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ Health Perspect. 1985 Oct; 62:109-14.
    View in: PubMed
    Score: 0.003
  40. Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1984 Dec; 5(12):1641-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.